Skip to main content

Table 1 Clinical findings of patients with amyotrophic lateral sclerosis and of control subjects

From: Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant

Case no. Age at death (years) Gender Diagnosis Postmortem delay (hours) Duration of illness (months) Percentage of VCP-positive nuclei
Control cases      
1 75 M Chronic lymphocitic leukemia 2.5 NA 0
2 75 M Cerebral infarction 1 NA 0
3 86 M Cerebral infarction 5 NA 0
4 75 M Meningitis 3 NA 1.7
5 83 F Intracerebral hemorrhage 12 NA 4
6 52 M Cerebral infarction 12 NA 8.9
7 50 F Myotonic Dystrophy 10 NA 0
8 60 M Myasthenia Gravis 2.5 NA 0
ALS cases       
9 54 F SALS 3.5 11 26.3
10 82 M SALS 1.5 14 0
11 62 M SALS 1.5 14 0
12 56 F SALS 22.5 20 0
13 65 M SALS 1.5 23 8.3
14 63 M SALS 1.5 23 15
15 64 M SALS 3 24 17.6
16 65 M SALS 16 24 94.1
17 58 F SALS 3.5 35 47.1
18 41 M VCP-ALS 2 48 7.7
  1. M male, F female, VCP Valosin-Containing Protein, SALS sporadic amyotrophic lateral sclerosis, VCP-ALS ALS with M158V VCP mutation.